KinderPharm, a full-service contract research organization (CRO) dedicated exclusively to pediatric drug development, has raised $1 million from a Series A, comprised of individuals, companies and angel investors. The $1 million investment will be used to further advance the clinical development of new medicines for children.
PRLog - Aug. 12, 2015 - Bringing Better Medicines to Children
The recently changed pharmaceutical industry’s perspective – as a result of legislative initiatives in both the US and Europe, and the increasing pressure from patients’ groups – created great opportunities for pediatric drug development. Our “Pediatric Center of Excellence” model is a unique resource of pediatricians, pharmacometricians, regulatory, drug safety and formulation scientists that develop pediatric drugs through all stages of development. Our seasoned teams bring expertise and insight to pharmaceutical companies of all sizes to help effectively navigate the complex pediatric regulatory environments in the US and Europe. With our partners we design, manage and conduct all aspects of pediatric product development including:
Waivers and deferrals
Age appropriate pediatric formulations
Juvenile toxicology studies
Protocol design
Dose extrapolation
PK/PD modeling and simulation
Population PK/sparse sampling strategies
PDP, PSP and PIP applications
Pediatric clinical trials
Regulatory strategy and submissions
For further information, please contact:
Martin Graham, PhD, Chief Executive Officer, (610) 458-1052
Janet Welsko, Chief Operating Officer, (610) 458-1052
Lynda Graham, MBA, Chief Financial Officer, (610) 458-1052
For media inquiries, please contact:
Kristin Liezenga, Business Development Executive, (610) 458-1502
Read Full Story - KinderPharm Raises $1 Million to Further Advance Pediatric Drug Development | More news from this source
Press release distribution by PRLog
KinderPharm Raises $1 Million to Further Advance Pediatric Drug Development
August 12, 2015 at 09:40 AM EDT